Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.78 |
| ▸ | RAB9A | P51151 | 13/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 6/20 | 0.78 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.78 |
| ▸ | RELA | Q04206 | 6/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7301810 | 0.85 | KMT2A (0.67) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL12523461 | 0.85 | KMT2A (0.67) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3366233 | 0.84 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL7300048 | 0.84 | RAB9A (0.74) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL23090417 | 0.83 | DHODH (0.62) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL11961607 | 0.81 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL21982901 | 0.79 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL7296050 | 0.79 | RAB9A (0.69) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL10000286 | 0.79 | RAB9A (0.59) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL32681139 | 0.78 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846760-B2 | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8653299-B2 | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120238628-A1 | DIHYDRONAPHTHALENE AND NAPHTHALENE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. | 2012-09-20 | — | — | US | disclosed |
| EP-0666250-B1 | Derivatives of N-(3-aminopropyl)-N-phenyl-5,6,7,8-tetrahydronaphthalene-2-carboxamide having neuroprotective and anti-ischemic properties, their preparation and their use, in therapy | SYNTHELABO (FR) | 1998-02-11 | — | — | EP | disclosed |
| US-5663183-A | CEREBRAL DISORDERS | SYNTHELABO (FR) | 1997-09-02 | — | — | US | disclosed |
| US-5550162-A | TREATMENT AND PREVENTION OF CEREBRAL DISORDERS | SYNTHELABO (FR) | 1996-08-27 | — | — | US | disclosed |
| EP-0666250-A1 | Derivatives of N-(3-aminopropyl)-N-phenyl-5,6,7,8-tetrahydronaphthalene-2-carboxamide having neuroprotective and anti-ischemic properties, their preparation and their use, in therapy | SYNTHELABO (FR) | 1995-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238628-A1 | DIHYDRONAPHTHALENE AND NAPHTHALENE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR2, FPR3 | NPC1 646/4885RAB9A 3357/4885SMN1; SMN2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.